Symbols

SGEN(Delisted)

Seagen·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SGEN

Seagen Inc.

A biotechnology company that develops and commercializes targeted therapies to treat cancer

Industry

Established Date

07/15/1997

Listing Date

03/06/2001

Exchange

NASDAQ Stock Exchange

Full-time Employees

3,256

Fiscal Year Ends

12-31

Website

www.seagen.com

Security Type

Common stock

Office address

21823 30th Drive SE , Bothell, WA 98021

Business

Introduction

Seagen Inc., was incorporated in Delaware on July 15, 1997. The company is a global biotechnology company dedicated to discovering, developing and commercializing transformable cancer drugs that can make a significant impact on people's lives. The company is headquartered in Seattle, Washington, and has branches in California, Canada, Switzerland and the European Union.

Company Financials

EPS

SGEN has released its 2023 Q3 earnings. EPS was reported at -1.15, versus the expected -0.8, missing expectations. The chart below visualizes how SGEN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SGEN has released its 2023 Q3 earnings report, with revenue of 648.65M, reflecting a YoY change of 27.11%, and net profit of -215.79M, showing a YoY change of -13.09%. The Sankey diagram below clearly presents SGEN's revenue sources and cost distribution.